Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of IN-105 in Type 2 Diabetes
NCT03392961Phase 1Completed
- Sponsor
- Biocon
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing IN-105 (Insulin Tregopil) with Placebo (2 arms). Primary endpoints: Area under the plasma concentration-time curve from dosing to last measurable concentration, Maximum observed plasma drug concentration and 3 more. Started Mar 2014; status: completed.
02
Drugs
insulin tregopil
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03392961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392961.